The response deadline has passed. Review the details for future reference or to track similar opportunities.
The Food and Drug Administration is acquiring Progenesis QI software to support metabolomics data analysis for scientific research and regulatory review, requiring robust peak detection, alignment, and statistical analysis capabilities for complex mass spectrometry datasets.
Acquisition of Progenesis QI software to enable advanced metabolomics data processing, including peak detection, alignment, normalization, and statistical analysis of high-resolution mass spectrometry data for FDA scientific programs.
No description available
Get matched to contracts like this daily
Free AI-powered contract matching for your business.